GLP1R and obesity due to melanocortin 4 receptor deficiency: Patients using GLP-1 RAs compared with not using GLP-1 RAs were more likely to be female (3502 [59.0%] vs 203 288 [56.4%]), to be aged 46 to 62 years (3629 [61.2%] vs 171 063 [47.4%]), to live in the South (3077 [51.9%] vs 162 278 [45.1%]), and to have been diagnosed with both obesity and diabetes (2819 [47.5%] vs 24 635 [6.8%]), hypertension (4127 [69.6%] vs 146 736 [40.7%]), or chronic kidney disease (378 [6.4%] vs 10 436 [2.9%]) (Table 1).